AOCI at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's AOCI?
- Arbutus Biopharma Corporation (ABUS) reported AOCI of -$48.2M in Q1 2026.
- How has Arbutus Biopharma Corporation's AOCI changed year-over-year?
- Arbutus Biopharma Corporation's AOCI decreased by 0.1% year-over-year, from -$48.17M to -$48.2M.
- What is the long-term trend for Arbutus Biopharma Corporation's AOCI?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's AOCI has grown at a -0.0% compound annual growth rate (CAGR), from -$48.17M to -$48.1M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.